FLT3 Amplification

CI-VAR-00000239Explore in graph →CIViC 2619

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm3
FLT3 Amplification	Regorafenib Anhydrous	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID7102 A patient with metastatic colon cancer who was previously treated with more than 3rd line cytotoxic chemotherapy was found to have FLT3 amplification and then received regorafenib showing partial resp… (full text at CIViC) PMID 27906677 · Lim et al., 2017 · Open in CIViC	civic
FLT3 Amplification	Sorafenib	Predictive	C	Supports Sensitivity Response	3	submitted	EID7103 Treatment with sorafenib of a patient with metastatic colorectal cancer and FLT3 translocation who had previously been heavily treated showed significant symptomatic and laboratory improvement with so… (full text at CIViC) PMID 25848357 · Moreira et al., 2015 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.